Global Urinary Tract Infections Market is estimated to grow at a CAGR of 3.62% through the forecast period 2019 to 2027
Global
Urinary Tract Infections Market: Information By Drug Class (Quinolones
(Ciprofloxacin, Enoxacin, Norfloxacin, Ofloxacin, Pefloxacin, Fleroxacin),
Β-Lactam & Cephalosporins (Amoxicillin-Clavulanate, Cefdinir, Cefaclor,
Cefpodoxime-Proxetil), Aminoglycosides, Penicillin, Azoles), Application
(Urethritis, Cystitis, Pyelonephritis), Pathogen (Escherichia coli,
Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis,
Enterococcus faecalis), End-User (Hospitals, Clinics, Self-Administered) and
Region (Americas, Europe, Asia-Pacific, Rest of the World) - Forecast till 2027
Urinary Tract Infections Market Highlights
Global Urinary Tract Infections Market is
expected to register a CAGR of 3.62% during the forecast period and is expected
to hit USD 12,513.1 Million by 2027.
A urinary tract infection (UTI)
is an infection in any part of the urinary system such as kidneys, ureters, bladder,
and urethra. UTIs can be caused for a variety of causes, including unsafe sex,
lack of hygiene, and diabetes. UTIs are more common in women than men due to
inherent complications in the female reproductive system. According to the
World Health Organization, 1 million hospitalizations of women occur each year
due to UTIs, which affects almost half of the female population around the
world.
The growth of the global
urinary tract infections market is attributed to the increasing prevalence of
diabetes and kidney stones. The launch of combination drugs is also resulting
in market growth. The rise in research & development (R&D) of a novel
class of antibiotics for UTIs is also expected to aid in the growth of the
market. For instance, in August 2020, researchers at the California Polytechnic
State University reported the development of a new class of antibiotics for
UTIs, which targets bacterial iron uptake, at the American Chemical Society
(ACS) Fall 2020 Virtual Meeting & Expo. Moreover, in July 2019, The US Food
and Drug Administration has approved Merck & Co., Inc.’s Recarbrio
(imipenem, cilastatin, and relebactam), an antibacterial drug to treat adults
with complicated urinary tract infections (cUTI) and complicated
intra-abdominal infections (cIAI).
Segment
Analysis
Global Urinary Tract Infections
Market has been divided based on drug class, application, pathogen, and end
user. The market, based on drug class, has been segmented into quinolones,
β-lactam & cephalosporins, aminoglycosides, penicillin, and azoles. The
quinolones are further sub-segmented into ciprofloxacin, enoxacin, norfloxacin,
ofloxacin, pefloxacin, and fleroxacin. The cephalosporin is divided into
avycaz, cedax, cefdinir, and cefditoren. β-lactam is further segmented into
amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime-proxetil.
The market, based on
application, has been bifurcated into urethritis, cystitis, and pyelonephritis.
The market, based on pathogen, has been bifurcated into Escherichia coli,
Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, and
Enterococcus
faecalis. On the basis of
end-user, the global urinary tract infections market has been classified as
hospitals, clinics, self-administered, and others.
Request
Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/6138
Regional
Analysis
The global UTI market, on the
basis of region, is divided into the Americas, Europe, Asia-Pacific, and the
Middle East & Africa. In 2019, the Americas accounted for the largest share
of the global market. This large share is majorly attributed to the presence of
key manufacturers, the rising prevalence of UTIs, and the growing aging woman
population in the region. Europe is the second-largest regional market in terms
of revenue. Urinary disorders account for a tremendous economic burden in
Europe. The high-income countries, the EU5 (France, Germany, Italy, Spain, and
the UK), typically spend 2–3% of their annual health budget on the treatment of
urinary disease as per a bulletin published by the WHO.
Asia-Pacific is expected to be
the fastest-growing market for UTI during the forecast period. This can be
attributed to the developing economies and highly populated countries such as
China, India, and South Korea. The African market is growing and will continue
to grow at a steady pace. The rapid urbanization in these countries has led to
increased exposure to numerous environmental toxins, a highly infectious
disease burden, and rising incidences of non-communicable diseases.
Key
Players
MRFR recognizes the following
companies as the Key Players in the Global Urinary Tract Infections Market—
Pfizer Inc, Novo Nordisk A/S, Novartis Ag, Merck & Co., Inc, Eli Lily and
Company, Allergan, Cipla Inc, Teva Pharmaceuticals, GlaxoSmithKline Plc, and
Bayer AG.
Key
Findings of the Study
Global Urinary Tract Infections
Market was valued at USD 12,513.1 million and is expected to register a CAGR of
3.62% during the assessment period.
The Americas accounted for the
largest share of the global market, majorly attributed to the presence of major
manufacturers, rising prevalence of urinary tract infection, and the growing
aging woman population in the region.
Based on drug class, the
quinolones segment accounted for the largest market share of 41.57% in 2019.
Based on application, the
urethritis segment dominated the market with a value share of 40.79% in 2019.
Based on the pathogen, the
Escherichia coli segment accounted for the largest market share of 65.59% in
2019, with a market value of USD 6,225.31 million.
Based on end-user, the hospital
segment dominated the market with a value share of 42.19% in 2019.
Browse Detailed TOC with
COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/upcoming-reports/urinary-tract-infection-market-6138
About
Market Research Future:
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email:
sales@marketresearchfuture.com
Comments
Post a Comment